Hematologist
CION Cancer Clinics
Primary or secondary myelofibrosis: what the label tells you | CION Cancer Clinics
Primary myelofibrosis starts on its own. Secondary myelofibrosis grows out of an earlier polycythaemia vera or essential thrombocythaemia, often after many years. Both scar the bone marrow, cause the same symptoms and are treated in much the same way. The label mainly changes how your history is read and which risk score is used. Here is how doctors tell them apart, and what it does and does not change. At CION Cancer Clinics, every leukaemia, MDS and MPN case is reviewed by our haematologist and discussed at a tumour board before a plan is agreed.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What is the difference between primary and secondary myelofibrosis?
- How do the two compare on paper?
- Which conditions can come before myelofibrosis?
- How does your haematologist tell which one you have?
- Does the difference change your treatment or outlook?
- What do people often misunderstand about secondary myelofibrosis?
- Common questions about primary and secondary myelofibrosis
The short answer
What is the difference between primary and secondary myelofibrosis?
The difference is where it started. Primary myelofibrosis begins on its own, with no earlier blood condition. Secondary myelofibrosis develops in someone who already had polycythaemia vera or essential thrombocythaemia, two related blood conditions, often for many years.
What stays the same
In both, the bone marrow fills with scar tissue and struggles to make healthy blood. The symptoms are the same: tiredness, a swollen spleen, night sweats, weight loss and itching. The tests used to confirm it are the same, and the medicines used to treat it are largely the same.
What changes
The history changes how the doctor reads your reports. It can change which risk score is used, and it explains results that might otherwise look confusing, such as a raised red cell count years ago. It also changes the words on your report. Secondary myelofibrosis is written as post-PV or post-ET myelofibrosis, naming the condition it grew out of.
Why families ask
Often a parent has been on tablets and regular blood tests for years, and a new report now says myelofibrosis. The natural fear is that treatment failed. Usually it did not. This change is part of how these conditions can behave over time, even when they are well controlled.
Side by side
How do the two compare on paper?
Primary myelofibrosis
Secondary myelofibrosis
Starts on its own, with no earlier marrow condition
Follows earlier polycythaemia vera or essential thrombocythaemia
Written as PMF on the report
Written as post-PV MF or post-ET MF
Gene change may be JAK2, CALR, MPL or none
Usually the same gene change found years earlier
Risk usually scored with DIPSS or a related score
A score built for secondary disease may be used instead
Treated by risk, symptoms and spleen size
Treated the same way, with the earlier history in mind
Three starting points
Which conditions can come before myelofibrosis?
All three belong to the same family, called myeloproliferative neoplasms. They share gene changes, which is why one can turn into another.
Nothing before it
This is primary myelofibrosis. The scarring is the first thing found. Some people first have an early stage with little scarring, which can look very like essential thrombocythaemia on a blood test.
Only the marrow biopsy tells these two apart.Polycythaemia vera
The marrow made too many red cells, so the blood was thick. People often had regular blood removal and tablets to thin the counts.
Signs it is changing
- Blood removal no longer needed
- Haemoglobin now falling
- Spleen growing again
Essential thrombocythaemia
The marrow made too many platelets. Many people took a blood thinner and sometimes a tablet to lower the platelet count.
Signs it is changing
- Platelets falling without a dose change
- New tiredness or night sweats
- Teardrop-shaped cells on the blood film
Not sure whether this applies to you?
Ask an oncologistHow doctors decide
How does your haematologist tell which one you have?
Your full history
Old blood counts matter here, and so do old prescriptions. A red cell or platelet count that was high years ago, or earlier treatment for either, points strongly to secondary disease. Bring every old report, however faded.
Gene results
The lab looks for JAK2, CALR and MPL changes. A result that matches an earlier test supports the idea that one condition has grown into the other. A wider gene panel may also be sent, because some extra changes affect the risk score.
The bone marrow biopsy
A small core of marrow, taken from the hip, is examined for scar tissue and graded. This is the test that confirms myelofibrosis and separates early primary disease from essential thrombocythaemia.
Putting it together
No single result decides it. Your haematologist reads the history, the counts, the spleen size and the marrow together before naming it. If the picture is unclear, the biopsy slides may be reviewed a second time, or a repeat test planned after a few months of watching.
What it means for you
Does the difference change your treatment or outlook?
For most people, treatment is decided by risk, symptoms and spleen size, not by the label. A JAK inhibitor such as ruxolitinib may be used in either type, and low haemoglobin is managed the same way in both.
Where the label does matter
The risk score is the main place. Scores designed for primary disease can misjudge risk in secondary disease, so a separate score may be used. A different score can put you in a different risk group, and that group guides decisions such as whether a stem cell transplant is worth discussing. CION's haematology team can review your case and coordinate referral to a transplant centre where it is appropriate.
Earlier medicines
If you were already taking a tablet for polycythaemia vera or essential thrombocythaemia, your team will decide whether it continues, changes or stops. Do not change it yourself because a new report has arrived.
What this page cannot tell you
Neither type is simply better or worse. Outlook depends on age, blood counts, symptoms and gene results together. Only your haematologist, with your own reports, can place you in a risk group. Ask them which score they used, which group it puts you in, and what would make them change the plan at your next visit.
Commonly believed
What do people often misunderstand about secondary myelofibrosis?
"The earlier treatment failed, or the doctor missed something."
Change over time is part of how these conditions can behave, even with good control. Earlier tablets reduce the risk of clots and bleeding; they are not known to reliably stop the marrow scarring later.
"Secondary means it is a milder, second-level problem."
Secondary only describes where it came from. It is not a grade of how serious it is. Some people with secondary disease need treatment soon; others are watched for a long time.
"We should stop the old tablets now it has changed."
Stopping a medicine suddenly can cause problems of its own. Any change to earlier treatment is made by your haematologist, after the new diagnosis is confirmed.
"A normal gene test means it cannot be myelofibrosis."
Some people with primary myelofibrosis have none of the three common gene changes. The marrow biopsy, not the gene test alone, confirms the diagnosis.
Did you know
Old blood reports are some of the most useful papers you can bring. A platelet or red cell count from years ago can change how today's marrow report is read, so keep them together in date order, even the handwritten ones.
Questions we are asked
Common questions about primary and secondary myelofibrosis
My father had polycythaemia for years. Is this now myelofibrosis?
It may be, if his counts have changed, his spleen has grown or he has new sweats and weight loss. It cannot be confirmed from symptoms or a blood count alone. A bone marrow biopsy is needed. Bring every old report to the appointment so the history can be read properly.
Is secondary myelofibrosis more dangerous than primary?
Not as a rule. The label does not decide how serious it is. Age, haemoglobin, other counts, symptoms and gene results decide the risk group, and those vary from person to person. Your haematologist will explain which group you fall into and what that means for your plan.
Can early primary myelofibrosis be mistaken for another condition?
Yes. An early stage with little scarring can look like essential thrombocythaemia, because platelets are high in both. The difference matters, because the outlook and follow-up differ. A careful bone marrow biopsy read by an experienced pathologist is how they are told apart.
Will the gene result change now it is secondary?
Usually the main gene change stays the same as the one found earlier. Your team may send a wider gene panel, because extra changes can affect the risk score. Ask whether that test is needed for your decisions and where it will be done.
Does the treatment differ between the two?
Mostly no. Both are treated according to risk, symptoms, spleen size and haemoglobin. The same medicines are used. The main difference is the risk score chosen, which can shape bigger decisions such as whether a transplant is worth discussing.
Can I stop my old blood-thinning tablet now?
Please do not stop or change it on your own. Clot risk does not disappear because the diagnosis has changed, and bleeding risk may have changed too. Your haematologist will review every medicine you take once myelofibrosis is confirmed.
Could this happen to my brother or children?
These gene changes are acquired during life, not usually inherited, so relatives do not need routine testing. A family link is uncommon. If several relatives have had blood conditions, tell your haematologist, who will decide whether it needs looking into.
What should I bring to the appointment?
Bring every blood count you can find, older reports first, plus any marrow, gene and ultrasound reports, and a list of all tablets taken now and in the past. Bring the family member who helps with decisions. Write your questions down before you come.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- Leukemia & Lymphoma Society — Myelofibrosis
- National Cancer Institute — Chronic Myeloproliferative Neoplasms Treatment (PDQ) - Patient Version
- Leukemia & Lymphoma Society — Myeloproliferative neoplasms
- Blood Cancer UK — Understanding blood cancer
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Talk to us
A new report says myelofibrosis?
Send us the new report with your older blood counts. Our haematology team will read them together and explain what has changed. One helpline serves every CION centre.